Abstract
FQAD is a comparatively new disease entity. Although it is described and defined by the FDA, the criteria are not suitable for bedside and practical use.
In order to enable a reliable and reasonably prompt diagnosis of this quite common syndrome, the clinical picture has been delimited here by an algorithm with clear diagnostic criteria.
This provides the clinician with a simple diagnostic tool to assist in confirming or ruling out FQAD.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
FDA/CDER Drug Information Webinar. “Fluoroquinolone-Associated Disability” (FQAD). April 4, 2017.
Bell DS. The disease of a thousand names. Lyndonville, NY: Pollard Publications; 1991.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Pieper, S. (2021). Diagnostic Criteria of the FQAD. In: Fluoroquinolone-Associated Disability (FQAD) - Pathogenesis, Diagnostics, Therapy and Diagnostic Criteria . Springer, Cham. https://doi.org/10.1007/978-3-030-74173-0_6
Download citation
DOI: https://doi.org/10.1007/978-3-030-74173-0_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-74172-3
Online ISBN: 978-3-030-74173-0
eBook Packages: MedicineMedicine (R0)